GlassScriptPhysician profile
Manish Pandya
NPI 1326145392
$1,983.15
in general payments reported to CMS, 2019-2025
17 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.45 · 2020: $36.93 · 2021: $69.95 · 2022: $83.12 · 2023: $153 · 2024: $265 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,129 · Food and Beverage: $503 · Education: $75.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,129.10 |
| Food and Beverage | $503.49 |
| Education | $75.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $1,199.29 | 2025 | Renal - Chronic |
| Amgen INC. | $127.20 | 2021-2025 | Tavneos |
| Mozarc Medical US LLC | $122.67 | 2024 | Chameleon |
| Novo Nordisk INC | $87.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.39 | 2020-2022 | |
| Medtronic, INC. | $64.61 | 2022-2025 | Ellipsys Vascular Access System, Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $57.37 | 2024 | |
| Lilly USA, LLC | $53.33 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $37.96 | 2023-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $28.83 | 2022-2024 | Lupkynis |
| Travere Therapeutics, INC. | $28.47 | 2023 | |
| Calliditas Therapeutics US INC. | $26.01 | 2025 | Tarpeyo |
| Insulet Corporation | $20.45 | 2021 | |
| Vifor Pharma, INC. | $19.13 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.33 | 2025 | Terlivaz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Pandya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.